PACS Group (PACS) has an average rating of Buy and mean price target of $48.83, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $40.72, Change: $-0.58, Percent Change: -1.40%
Jacqueline F Moloney, Director, on May 13, 2026, sold 1,400 shares in Mks (MKSI) for $446,586. Following the Form 4 filing with the SEC, Moloney has control over a total of 9,775 common shares of the company, with 9,775 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1049502/000104950226000082/xslF345X05/form4.xmlPrice: $312.67, Change: $-4.64, Percent Change: -1.46%
Doximity (DOCS) could face near-term pressure from slowing growth after issuing weaker-than-expected guidance, though strong user engagement trends and expanding artificial intelligence opportunities continue to support the stock's long-term outlook, Morgan Stanley said in a note Thursday.The company reported fiscal Q4 revenue of $145 million, up 5% from a year earlier and slightly above Wall Street estimates. However, the company guided fiscal Q1 revenue below Wall Street estimates and forecast fiscal 2027 revenue growth of 4% at the midpoint, disappointing analysts who expected stronger trends in the healthcare digital advertising market, according to the note.The investment firm said the stock could remain in the "penalty box" in the near term, as it cited several "positives that will likely get overlooked," including a roughly 30% increase in active prescribers using Doximity's workflow tools to more than 800,000 users.The firm also cited early traction for the company's AI search product, which won deals with top pharmaceutical companies within weeks of launch.Morgan Stanley lowered the price target on Doximity to $35 from $49, while maintaining an overweight rating.Shares of Doximity were falling more than 26% in late morning trading Thursday.Price: $17.24, Change: $-6.15, Percent Change: -26.29%
Prestige Consumer Healthcare (PBH) reported weaker-than-expected Q4 results and issued 2026 guidance below consensus, with the shortfall driven primarily by supply constraints in Clear Eyes and broader execution pressures, Oppenheimer said in a Thursday note.The analyst said adjusted EPS and revenue both missed expectations in the quarter, while the 2026 outlook came in below Street estimates, reflecting headwinds from recent acquisitions, elevated leverage and a more uncertain consumer environment.Oppenheimer noted that management introduced a medium-term framework calling for roughly 10% annual revenue growth and about 8% EPS compound annual growth rate, supported by portfolio expansion, Clear Eyes recovery, and contributions from recent acquisitions.The report added that Prestige's planned acquisition of LaCorium Health for about $150 million is expected to strengthen its skincare portfolio and add incremental growth, while the firm updates its estimates pending further clarity on 2026 assumptions.Oppenheimer downgraded the stock to perform from outperform and removed its $65 price target.Shares of Prestige Consumer Healthcare were down more than 12% in Thursday trading.Price: $45.28, Change: $-6.53, Percent Change: -12.60%